This reference desk brings together selected obesity-drug research records and MyWeightLab-created visualizations. Journalists, researchers and editors can inspect the underlying evidence, download the public data and check the limitations before citing a finding.
Drug pipeline
6 selected medicine records. Separate US FDA and EU EMA facts; clinical development never substitutes for authorisation.
Explore the Drug TrackerClinical studies
6 source-linked trial records. Registry enrollment and published analysis populations are retained separately.
Explore the Clinical Trial TrackerResearch arithmetic
A percentage-weight-change calculator explains the formula and its limits. Inputs remain in the visitor’s browser.
Use the percentage calculatorDownload the source-linked datasets
API schema version 1. Selected data are checked as of . Each record has its own source date and scope. Downloads preserve the current accepted snapshot; they are not a comprehensive approval database.
The existing public API caches responses for five minutes, provides an ETag and limits repeated requests. It contains public evidence records only.
Methodology and evidence boundaries
Regulatory statements start with FDA or EMA documents. Trial identifiers, phases and registry milestones come from ClinicalTrials.gov. Published population sizes, durations and results are separately traced to original peer-reviewed study abstracts. Sponsor announcements are identified as sponsor evidence, never substituted for a regulator’s decision.
The drug and trial downloads use a selected accepted snapshot. Each field retains its source and verification date. A registry date is not an approval date; registry enrollment can differ from a publication’s randomized or analysis population. A date when a file was generated is not a new medical review.
The charts below transcribe numerical values from the identified original abstracts, with a fresh check of the source for each chart. That check does not refresh every regulatory field in the downloadable snapshot. Full texts, supplements and independent clinical review were not completed for this chart set.
Results from different trials are not interchangeable: eligibility, background care, dose escalation, follow-up, missing-data methods and estimands differ. We do not create a drug efficacy league table, predict an individual’s response or infer missing confidence intervals. Historical trial-arm dose labels are not dosing recommendations.
Selected FDA / EU authorisation milestones
Product names, jurisdictions and indication changes are kept separate. These selected historical dates are not a complete approval timeline or a substitute for the current prescribing label. An initial EU authorisation date does not date every later indication or formulation.
| Date | Jurisdiction / product | Event and scope | Primary source / checked |
|---|---|---|---|
| European UnionWegovy (semaglutide) | Initial EU marketing authorisationInitial authorisation date in the EMA EPAR; not the date of later formulation or indication changes. | EMAChecked 2026-10-04 | |
| European UnionMounjaro (tirzepatide) | Initial EU marketing authorisationInitial product authorisation for type 2 diabetes; this is not the date of the later weight-management indication extension. | EMAChecked 2026-10-04 | |
| United StatesZepbound (tirzepatide) | FDA chronic weight-management approvalAdults with obesity, or overweight with at least one weight-related condition, alongside reduced-calorie diet and increased physical activity. Consult the current label for all conditions. | FDAChecked 2026-10-04 | |
| United StatesZepbound (tirzepatide) | FDA obstructive sleep apnoea indicationModerate-to-severe obstructive sleep apnoea in adults with obesity, alongside reduced-calorie diet and increased physical activity. This is an additional indication, not the initial drug approval. | FDAChecked 2026-10-04 | |
| United StatesFoundayo (orforglipron) | FDA weight-management approvalAdults with obesity, or overweight with at least one weight-related comorbid condition, alongside reduced-calorie diet and increased physical activity. No EU decision is inferred. | FDAChecked 2026-10-04 |
Within-trial evidence charts
Each chart compares arms within one trial. The three charts use different populations, follow-up periods and estimands. Reading them together does not establish which medicine works best.
STEP 1: semaglutide and placebo
Published mean body-weight changes within this randomized trial. Negative percentages indicate a decrease from baseline. This is not a cross-trial drug ranking.
- Population
- Adults with overweight or obesity, without diabetes; 1,961 enrolled.
- Analysis duration
- 68 weeks
- Estimand
- treatment-policy: regardless of discontinuation or rescue intervention
- Original abstract rechecked
| Historical research arm | Change from baseline | Study |
|---|---|---|
| semaglutide 2.4 mg trial arm | -14.9% | NCT03548935 |
| placebo | -2.4% | NCT03548935 |
Registry actual enrollment and published enrolled population both equal 1961.
Original STEP 1 study abstract · NCT03548935 registry
Only the original abstract was rechecked for these charts. Full papers, supplements and independent clinical review were not completed. Confidence intervals and safety findings are not represented by these selected mean values. Research-arm dose labels describe the historical protocol; they are not prescribing instructions.
SURMOUNT-1: tirzepatide and placebo
Published mean body-weight changes within this randomized trial. Negative percentages indicate a decrease from baseline. This is not a cross-trial drug ranking.
- Population
- Adults with overweight or obesity, without diabetes; 2,539 randomized.
- Analysis duration
- 72 weeks
- Estimand
- treatment-regimen (intention-to-treat)
- Original abstract rechecked
| Historical research arm | Change from baseline | Study |
|---|---|---|
| tirzepatide 5 mg trial arm | -15.0% | NCT04184622 |
| tirzepatide 10 mg trial arm | -19.5% | NCT04184622 |
| tirzepatide 15 mg trial arm | -20.9% | NCT04184622 |
| placebo | -3.1% | NCT04184622 |
Registry actual enrollment and published randomized population both equal 2539.
Original SURMOUNT-1 study abstract · NCT04184622 registry
Only the original abstract was rechecked for these charts. Full papers, supplements and independent clinical review were not completed. Confidence intervals and safety findings are not represented by these selected mean values. Research-arm dose labels describe the historical protocol; they are not prescribing instructions.
TRIUMPH-1: retatrutide and placebo
Published mean body-weight changes within this randomized trial. Negative percentages indicate a decrease from baseline. This is not a cross-trial drug ranking.
- Population
- Adults with obesity, without diabetes; 2,339 randomized.
- Analysis duration
- 80 weeks
- Estimand
- treatment-regimen (intention-to-treat)
- Original abstract rechecked
| Historical research arm | Change from baseline | Study |
|---|---|---|
| retatrutide 4 mg trial arm | -17.6% | NCT05929066 |
| retatrutide 9 mg trial arm | -23.7% | NCT05929066 |
| retatrutide 12 mg trial arm | -25.0% | NCT05929066 |
| placebo | -3.9% | NCT05929066 |
Registry actual enrollment 2335 differs from 2339 randomized in the paper; the reason was not established from these sources.
Original TRIUMPH-1 study abstract · NCT05929066 registry
Only the original abstract was rechecked for these charts. Full papers, supplements and independent clinical review were not completed. Confidence intervals and safety findings are not represented by these selected mean values. Research-arm dose labels describe the historical protocol; they are not prescribing instructions.
Citation and chart reuse
MyWeightLab-created chart artwork on this page is available under Creative Commons Attribution 4.0. Journalists and researchers may reproduce these charts with attribution to MyWeightLab, the original study citation, the stated source-check date and the relevant study context. Identify any changes you make. A normal source link helps readers verify the data; no particular link attribute or anchor text is required.
This permission covers our original chart design, not the original research papers, pharmaceutical branding, third-party figures or other materials that retain their own rights. Do not remove study context, imply author endorsement or turn the charts into a treatment recommendation.
Corrections and research enquiries
Please send a record URL and the primary source supporting a correction through the editorial contact page. See our fact-checking policy, corrections process and resources for journalists. This publication provides educational information and has no authority to diagnose, prescribe or provide individual medical care.